# Paratek Pharmaceuticals

> Paratek Pharmaceuticals is a Boston-based commercial-stage biopharmaceutical company built on tetracycline chemistry to fight drug-resistant bacterial infections. Its flagship antibiotic NUZYRA (omadacycline) is a once-daily oral and IV broad-spectrum drug approved by the FDA in 2018 for community-acquired bacterial pneumonia and acute skin infections, and it is also being developed under a major BARDA contract as a national-stockpile countermeasure against pulmonary anthrax. Paratek also originated SEYSARA (sarecycline) for acne. Now privately held by Gurnet Point Capital and Novo Holdings after a 2023 acquisition, the company positions itself as a defender of public health against the slow-moving pandemic of antimicrobial resistance.

- **Founded:** 1996
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** Stuart B. Levy (Co-founder, antibiotic resistance pioneer), Walter Gilbert (Co-founder, Nobel laureate)
- **Team size:** ~270 employees
- **Products:** NUZYRA (omadacycline), SEYSARA (sarecycline), XHANCE (fluticasone propionate)
- **Notable:** FDA approval of NUZYRA (omadacycline) in October 2018 for CABP and ABSSSI., FDA approval of an oral-only NUZYRA dosing regimen for CABP in June 2021., Awarded a BARDA Project BioShield contract worth up to ~$304 million for anthrax biodefense.

## Products & services

- **NUZYRA (omadacycline)** — Once-daily oral and intravenous broad-spectrum antibiotic, a modernized tetracycline approved by the FDA in October 2018 for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Also in development under BARDA for treatment and post-exposure prophylaxis of pulmonary anthrax.
- **SEYSARA (sarecycline)** — A narrow-spectrum tetracycline-derived oral antibiotic discovered by Paratek and developed/commercialized for moderate to severe acne vulgaris.
- **XHANCE (fluticasone propionate)** — A nasal spray product in Paratek's commercial portfolio for chronic rhinosinusitis and nasal polyps.

## Achievements

- FDA approval of NUZYRA (omadacycline) in October 2018 for CABP and ABSSSI.
- FDA approval of an oral-only NUZYRA dosing regimen for CABP in June 2021.
- Awarded a BARDA Project BioShield contract worth up to ~$304 million for anthrax biodefense.
- 100% survival of omadacycline-treated rabbits in a pilot pulmonary anthrax efficacy study versus 0% for placebo.
- Discovered sarecycline (SEYSARA), an FDA-approved acne antibiotic.
- Completed a U.S. onshoring program in 2024, making NUZYRA the only novel antibiotic with fully domestic supply and manufacturing.

## Latest updates

- **2024-11** — Announced completion of its U.S. onshoring program, making NUZYRA the only novel antibiotic with fully domestic supply and manufacturing capabilities.
- **2023-09** — Acquisition by Gurnet Point Capital and Novo Holdings A/S completed; Paratek became a privately held company.
- **2023-01** — Received a $36.4 million milestone payment for the second NUZYRA procurement under the BARDA Project BioShield contract.
- **2021-06** — FDA approved an oral-only NUZYRA dosing regimen for community-acquired bacterial pneumonia.

## Links

- Website: https://paratekpharma.com
- LinkedIn: https://www.linkedin.com/company/paratek-pharmaceuticals-inc-
- Twitter/X: https://twitter.com/ParatekPharma
- Facebook: https://facebook.com/paratekpharma

---

Profile page: https://yespress.io/paratek-pharmaceuticals
Published by YesPress — https://yespress.io
Last updated: 2026-06-20